Prescription for Better Access

Mark Hansan and Dr. Scott Howell
  • 5.0（17則評分）
  • 醫學
  • 隔週更新
Prescription for Better Access

With pharmaceutical and biotech manufacturers launching more high-cost specialty drugs and the insurance industry increasing the use of more restrictive barriers to access, those who need these medicines—the patients themselves—are caught in the middle, not only shouldering the cost of higher copays and deductibles, but for many, rationing or even abandoning treatment altogether. While manufacturers invest in programs to help navigate the challenges impeding access and affordability, the entire healthcare industry can agree -- the status quo is unsustainable. There has to be a better way. And two industry veterans have joined forces to co-host a new interview-focused podcast to help shape the future of patient access and affordability.

  1. 3 天前

    2025 Outlook with Stacie Dusetzina, Ph.D., Vanderbilt University

    In this episode, we sit down with Stacie Dusetzina, Ph.D., a leading health economist from Vanderbilt University Medical Center to discuss the critical healthcare and policy trends shaping 2025. From shifts in federal leadership to the evolving impact of the Inflation Reduction Act, our guest provides expert insights on what to expect in drug pricing, health insurance, and patient access in the coming year. We explore how the public and private sectors are addressing affordability challenges and highlight innovative approaches to improve access to essential medications. With a focus on the future, this conversation offers a thoughtful outlook on the policies and market dynamics set to redefine healthcare in 2025. Stacie Dusetzina, Ph.D., Vanderbilt University Vanderbilt University Medical Center A primer on copay accumulators, copay maximizers, and alternative funding programs CMS  FDA IRA Medicare Part D Pharmacy Benefit Managers (PBMs) Medicaid CMMI’s Medicaid group negotiation  COVID-19 Statins PCSK9 inhibitors Imatinib 340B Drug Pricing Program Questions or comments? Email us at comments@prescriptionforbetteraccess.com. Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

    48 分鐘

  2. 12月4日

    Cell and Gene Therapy Access Challenges

    In our second of three episodes in conjunction with members of ACCESS Forum, we engage with leading experts to uncover the multifaceted challenges of access and affordability in cell and gene therapies. Our conversation investigates how these treatments' innovative yet complex landscape leads to challenging regulatory pathways, pricing models, and reimbursement strategies.  Alicia Silver, MPP, Head of Cell and Gene Therapy, ADVI Health Eric Faulkner, President, Passage Health Associates ADVI Health Alliance for Regenerative Medicine ARPA-H Bespoke Gene Therapy Consortium Blue Bird Bio Blue Cross Blue Shield Medicare DRG Rates NICE (National Institute for Health and Care Excellence) Novartis Passage Health Associates REMS Program Single Case Agreements Spark Therapeutics Medical terminology referenced in this episode: Alzheimer's Aspheresis CAR T therapy Hemophilia Hepatitus C Luxturna Metachromatic leukodystrophy  Myeloablative Conditioning Sickle Cell Disease SMA treatment Spinraza Vaso Occlusive Crises Zolgensma

    53 分鐘

  3. 10月22日

    Global vs. US Drug Pricing and Market Access

    In this episode, we sit down with leading Market Access experts and members of ACCESS Forum to compare and contrast the drug pricing and access systems worldwide and the US. Our discussion delves into the distinct approaches taken by government vs. private markets, examining how regulatory environments, pricing controls, and reimbursement processes impact patient access to innovative therapies. We explore the challenges each approach faces, from cost pressures to affordability and access, and how they balance the interests of patients, governments, and pharmaceutical companies. Join us for a deep dive into how the global healthcare landscape is evolving and what lessons can be learned. Nikos Maniadakis, Ph.D., Professor, Health Management & Policy, University of West Attica Kimberly Baldwin, Senior Vice President, Value & Access, Ipsen Biopharmaceuticals Fauzea Hussain, Vice President, Public Policy, McKesson CMS (Centers for Medicare & Medicaid Services) European Medicines Agency Health technology assessments (HTAs) IRA (Inflation Reduction Act) Medicaid Medicare National Institute of Clinical Excellence (NICE) NCCN guidelines P&T committee (Pharmacy and Therapeutics Committee) PAP (Patient Assistance Program) Part B (Medicare) Part D (Medicare) Pharmacy Benefit Managers (PBMs) Quality-Adjusted Life Years Tricare Veterans Administration Medical terminology referenced in this episode: Cell and gene therapies (CGT) Insulin Orphan drugs Questions or comments? Email us at comments@prescriptionforbetteraccess.com.

    54 分鐘

  4. 9月12日

    22. Honoring the Work of Healthcare Advocates

    In this episode, we explore the evolving role of healthcare and patient advocates and how this profession has become an essential part of the healthcare system. We begin by defining what a healthcare advocate is and tracing the development of the profession over the years. Key milestones are discussed, such as establishing codes of ethics, training, and certification processes. We also share real-world examples of how advocates help patients navigate the complexities of healthcare, making a measurable impact on patient outcomes. The discussion covers the scale of advocacy in the U.S., examining the roles of professional advocates compared to family members and volunteers. We also address how advocates are helping patients overcome barriers to accessing and affording medicines. Finally, we look to the future of advocacy, discussing potential healthcare reforms, the impact of technology, and practical advice for patients seeking an advocate in today's challenging healthcare environment. Rachel Westlake, Managing Director, Coalition of Health Care Advocacy Organizations Danielle Marshall, Executive Director, Patient Advocate Certification Board Fred Larbi, Chief Operations Officer, HealthWell Foundation CHCAO Patient Advocate Cerification Board Healthwell Foundation Greater National Advocates NAHAC HealthAdvocateX Umbra Solace  Questions or comments? Email us at comments@prescriptionforbetteraccess.com. Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

    45 分鐘

  5. 8月20日

    Evolution of PBM's

    In this episode, we explore the evolution and future of the Pharmacy Benefit Management (PBM) industry with insights from two seasoned pharma managed care executives. We discuss the early role of PBMs, their acquisition by pharmaceutical companies, and subsequent industry consolidation. We examine how vertical integration of the PBMs transformed their business model, including the restricted formularies that gave rise to rebates. We also address evolving PBM-manufacturer relationships, the effects of public scrutiny, and predictions for key trends. Join us for a comprehensive look at the past, present, and future of PBMs, focusing on the changes needed to better serve patients. Steve Stefano, Managing Director, ReprizioRx  Steve.Stefano@repriziorx.com Bill Leonard, Managing Director, ReprizioRX wjl@repriziorx.com ReprizioRX PBMs IPA model HMO Medco Metro Containment Services Medicare Catastrophic Coverage Act of 1988 Merck SmithKline Beecham Eli Lilly 340B NDC blocks Group Purchasing Organizations (GPOs)  Medicare United Healthcare FTC CostPlusDrugs Questions or comments? Email us at comments@prescriptionforbetteraccess.com. Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

    45 分鐘

  6. 7月16日

    How Access Challenges Impact the Drug Development Pipeline

    In this episode, we dive into the pharmaceutical industry's research and drug development side and the real threat that today’s access and affordability challenges and policies pose to innovation. While innovation often starts in universities with government support, biotech, and pharma companies take on the tough, costly job of clinical trials, development, and approval of new drugs. Investment dollars are limited, only the most promising projects get funded, with an expectation there will be a return. However, our current drug payment process and policies like the IRA have added new considerations for investors, risking fewer new drugs being developed. Without changes, patients could face the closing of our nation's medicine cabinet, with fewer new treatments available. This would be an outcome that would be catastrophic for all of us. Erin Mistry, EVP and Chief Commercial Officer, Cormedix, Inc. Imran Nasrullah, JD., formerly VP & US Head of BD&L at Bayer, and now Founder, SNAP Life Sciences Research and development (R&D) FDA CF Foundation Vertex NIH AMR (antimicrobial resistance) The Pasteur Act HIV Malaria Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry Novo Nordisk Bets Up to $600 Million on Ozempic 2.0. Here's Why the Stock Is a Buy. Genentech Genzyme (Now Sanofi) Medicare IRA (Inflation Reduction Act) COVID-19 Questions or comments? Email us at comments@prescriptionforbetteraccess.com. Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

    49 分鐘

  7. 6月4日

    Interviews from Asembia’s AXS24 Summit, Part 2

    This is the second of two episodes dedicated to Asembia’s AXS24 Summit, where we were honored to be a media partner. In this episode, we learn from Sarah Butler, Chief Commercial Officer of ADVI Health and Lindsay Greenleaf, JD, MBA, Head of Federal and State Policy for ADVI Health how the 2024 election will impact patient access and affordability. Umar Afridi, Founder and CEO of Foundation Health, summarizes his session, From Opaque to Transparent: Transforming the Way We Pay for Drugs. Finally, we get a few minutes with Joe Boswell, the President of ACCESS Forum, leading an effort to create a network for market access professionals. ADVI: Sarah Butler (Chief Commercial Officer) Lindsey Greenleaf (Consulting and Government Affairs Head) R&D Inflation Reduction Act NCCN Compendia Part D CMS Pharmacy Benefit Managers (PBMs) Part B FTC and Office of Inspector General (IG) FTC's Section 6B study Foundation Health:Umar Afridi, Founder and CEO Session: "From Opaque to Transparent: Transforming the Way We Pay for Drugs." Pharmacy Benefit Managers (PBMs) Truepill API platforms International Access Professional Society:Joe Boswell. President GenMAV Asembia

    34 分鐘

  8. 5月24日

    Interviews from Asembia's AXS24 Summit, Part 1 of 2

    Asembia’s AXS24 Summit, a pinnacle of specialty drug and healthcare discussions, concluded earlier this month. We are thrilled to share that our podcast was selected as a media partner for this esteemed event. This is the first of two episodes dedicated to AXS24, where Scott and Mark had the opportunity to interview several key speakers and attendees. In this episode, we bring you the insights of Melissa Paige, a seasoned healthcare professional and President of the National Association of Medication Access & Patient Advocacy, who led a session on the Patient Financial Impact of IRA. We also present the perspectives of Renee Rayburg, RPh., VP, Clinical Strategy, Pharmaceutical Strategy Group and Morgan Lee, PhD, MPH, CPH, Senior Director, Research & Strategy, PSG, who are renowned for their study and session on Viewpoints in Specialty Drug Benefit Design. Melissa Paige, President, (NAMAPA) University of Virginia Health System Asembia Inflation Reduction Act Dr. Madelaine Feldman Renee Rayburg, Vice President Specialty Clinical Consulting, Artemetrx,  Morgan Lee, PhD, Senior Director, PSG Pharmacy Benefit Managers (PBMs) GoodRx 2024 Trends in Specialty Drug Benefits Report Medical terminology referenced in this episode: Generic ARBs Multiple Sclerosis Humira biosimilars Albuterol inhaler Email us:comments@prescriptionforbetteraccess.com. Follow us on X, LinkedIn, YouTube and Threads.

    36 分鐘
顯示全部 (26)

5
（滿分 5 顆星）
17 則評分

簡介

With pharmaceutical and biotech manufacturers launching more high-cost specialty drugs and the insurance industry increasing the use of more restrictive barriers to access, those who need these medicines—the patients themselves—are caught in the middle, not only shouldering the cost of higher copays and deductibles, but for many, rationing or even abandoning treatment altogether. While manufacturers invest in programs to help navigate the challenges impeding access and affordability, the entire healthcare industry can agree -- the status quo is unsustainable. There has to be a better way. And two industry veterans have joined forces to co-host a new interview-focused podcast to help shape the future of patient access and affordability.

資訊

  • 創作者
    Mark Hansan and Dr. Scott Howell
  • 活躍年代
    2023年 - 2024年
  • 集數
    26
  • 年齡分級
    兒少適宜
  • 版權
    © 2024 Prescription for Better Access Mark Hansan and Dr. Scott Howell
  • 節目網站
    Prescription for Better Access

你可能也會喜歡

若要收聽兒少不宜的單集，請登入帳號。

隨時掌握此節目最新消息

登入或註冊後，即可追蹤節目、儲存單集和掌握最新資訊。
選取國家或地區

非洲、中東和印度

亞太地區

歐洲

拉丁美洲與加勒比海地區

美國與加拿大